Abstract: Phenyl-alkane-carboxylic acids of the formula ##STR1## wherein A is an aryl, aralkyl or arylvinyl radical optionally substituted by hydroxy, halogen, trifluoromethyl, alkyl, alkylthio, alkoxy, alkenyloxy, alkoxyalkoxy, alkyl-substituted amino, aryloxy or alkoxy-substituted aryloxy, or is an aryloxyalkyl or arylthioalkyl radical, or a heterocyclic ring system optionally substituted by halogen, alkyl or alkoxy,Y is a valency bond or an unbranched or branched lower alkylene radical containing up to 3 carbon atoms,X is a straight or branched, saturated or unsaturated divalent aliphatic hydrocarbon radical containing 2 to 8 carbon atoms, there being at least 2 carbon atoms between the benzene ring and the carboxyl group, andR is a hydrogen atom or a lower alkyl radical, as well as physiologically compatible salts, esters and amides thereof, exhibit hypoglycaemic and hypolipidaemic activity.

Abstract: Indole-carboxylic acid compounds of the formula: ##STR1## wherein R.sub.1 is lower alkyl or alkoxy radical or halogen;R.sub.2 is halogen; lower alkyl or alkoxy radical; orR.sub.1 and R.sub.2 can together also form an alkylene bridge containing 3 to 5 carbon atoms, which can optionally contain one or more double bonds; and, but less preferably, when R.sub.1 is a lower alkyl or alkoxy radical, R.sub.2 can also be a hydrogen atom, and physiologically compatible salts and esters thereof,Are outstandingly effective as blood sugar-lowering agents.

Abstract: A blood sugar lowering composition comprising as the active material particulate glibenclamide having a surface area of about 3 to 10 m.sup.2 /g in admixture with a pharmacologically acceptable non-ionic wetting agent present in about 2 to 20 times the weight of the glibenclamide. The preferred wetting agent is polyoxyethylene stearate present in about 5 to 10 times the weight of the glibenclamide.

Abstract: Benzenesulfonyl-ureas of the formula ##STR1## wherein X represents ##STR2## IN WHICH Z represents hydrogen, halogen, a trifluormethyl group, an alkyl or an alkoxyl radical in 4- or 5-position, or ##STR3## Y represents --CH.sub.2 --CH.sub.2 --, --CH--(CH.sub.3)--CH.sub.2 --or --CH.sub.2 --CH--(CH.sub.3)--,R represents a radical ofA. pentamethylene-imine, which may be substituted by 1 to 3 methyl group or by an endoalkylene group of 1 to 3 carbon atoms,B. hexamethylene-imine, which may be substituted by an endoethylene group in .beta.-.epsilon.-position,C. heptamethylene-imine,D. hexahydro-isoindoline, tetrahydro-isoindoline, 4,7-endoalkylene-hexahydro-, 4,7-endoalkylene-tetrahydro-isoindoline, the endoalkylene group of which may contain 1 - 2 carbon atoms and the double linkage of the tetrahydro group being in 5,6-position,E. N-3-azaspiro-[5,5]-undecane,F. the groups ##STR4## and their pharmaceutically acceptable alkali- or alkaline earth-metal salts.

Abstract: Sulfonyl-ureas of the formula ##STR1## wherein X represents a heteroaromatic 5- or 6-ring substituted, if desired, by one or two methyl groups and/or annellated with benzene, which ring may contain in addition to a nitrogen atom a further nitrogen, oxygen or sulfur atom and which, in vicinal position to the nitrogen atom, is linked to the rest of the molecule portion, R is alkyl having 1 to 3 carbon atoms, R.sup.1 is alkyl having 3 to 6 carbon atoms, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl, cycloalkenyl, alkylcycloalkenyl having each 5 to 9 carbon atoms, cyclohexenylmethyl, chlorocyclohexyl, bicycloheptenylmethyl, bicycloheptylmethyl, bicycloheptenyl, bicycloheptyl, nortricyclyl, adamantyl, benzyl, which as substance or in form of the salts thereof have hypoglycemic properties and are distinguished by a strong and continuous lowering of the blood sugar level, process for preparing them as well as pharmaceutical preparations containing the sulfonyl-ureas as an active substance.

Abstract: New biguanide compounds of the formula: ##STR1## wherein A is saturated or unsaturated cycloaliphatic hydrocarbyl, and the physiologically compatible salts thereof; display outstanding anti-diabetic effectiveness in the treatment of diabetes mellitus, without showing the typical side effects of biguanide treatment, viz., lactacidosis.

Abstract: New indole derivatives of the formula ##STR1## wherein R.sub.1 and R.sub.2, which may be the same or different, are hydrogen or halogen or lower alkyl or, taken together, represent a --CH=CH-CH=CH- bridge, with the proviso that R.sub.1 and R.sub.2 are not both hydrogen, and wherein, when R.sub.2 is halogen or alkyl, R.sub.1 can also be alkoxy;Are outstandingly effective in blood sugar lowering action in mammals.

Abstract: New heterocyclic-substituted nebularin compounds of the formula: ##SPC1##WhereinR.sub.1 is hydrogen, halogen or amino;R.sub.2 and R.sub.3, which may be the same or different, are hydrogen, hydroxyl, lower alkyl, alkoxy or hydroxyalkyl; andn is 2 or 3 or, when R.sub.1 is a halogen atom or an amino group, n can also be 1; and the pharmacologically compatible salts thereof;Are outstandingly effective in reducing body fat levels in mammals, e.g., the concentration of free fatty acids, of triglycerides and of cholesterol in serum.

Abstract: Rapidly resorbable particulate glibenclamide having a particle surface area of active material of at least 3 m.sup.2 /g is produced by precipitating the active material from its solution in an organic solvent or in water or aqueous alcohol, preferably rendered alkaline, using water which is preferably acidified.

Abstract: New N(6)-disubstituted adenosine compound of the formula ##SPC1##WhereinR.sub.1 is lower alkyl substituted by at least one of hydroxyl, alkoxy or acyloxy; or is cycloalkyl or straight-chained or branched lower alkenyl;R.sub.2 and R.sub.3 are hydrogen, halogen, or nitro or lower alkyl, alkoxy or alkylthio andR.sub.4 is hydrogen or acyl; when R.sub.4 is acyl, R.sub.1 can also be lower alkyl;And the pharmacologicaly compatible salts thereof; exhibits shown anti-lipolytic, anti-hyperlipaemic and anti-hypercholesterolaemic action.